Methods for attenuating viral infection and for treating lung injury
AssigneeSpiritus Therapeutics, Inc.
InventorsJodi Gurney, Robin Smith
Life of this patent
Estimating the term…
Loading patent…
AssigneeSpiritus Therapeutics, Inc.
InventorsJodi Gurney, Robin Smith
Estimating the term…
The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.
A precision medicine method for optimizing therapeutic benefit for a susceptible subject at risk of a chronic complication of an acute acute injury to a tissue, organ or system caused by a severe infection with a respiratory virus, comprising:
(canceled)
A method of diagnosing and treating a subject at risk of a chronic complication of an acute injury to a tissue, organ or system caused by a severe infection with a respiratory virus in a susceptible subject comprising
A method of attenuating a severe infection with a respiratory virus in a susceptible subject and reducing risk of a chronic complication of the severe infection comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a population of EVs comprising one or more of an miRNA derived from normal, healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition upregulates expression of miR-29a, downregulates miR-199-3p, or both, wherein the chronic complication comprises an inflammatory immune response that reduces function of the tissue, organ or system of the subject compared to a healthy control;
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for resuscitating donor lungs comprising administering ex vivo a therapeutic amount of a pharmaceutical composition comprising a population of EVs comprising one or more of an miRNA derived from normal, healthy MSCs, an miR-29a mimic, an miR-199-3p inhibitor, and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition upregulates expression of miR-29a, downregulates miR-199-3p, or both, wherein the method restores lung function.
Dependencies are inferred from the claim text.